{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:23Z","timestamp":1794047423756,"version":"4.8.0"},"reference-count":33,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"8","license":[{"start":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T00:00:00Z","timestamp":1674691200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Although classic Hodgkin lymphoma (cHL) is highly curable with current treatment paradigms, therapy fails in 10-25% of patients. This prospective multicenter phase II study attempted to investigate the efficacy and safety of the combination of tislelizumab with gemcitabine and oxaliplatin (T-GemOx) in relapsed or refractory cHL. Participants received six to eight courses of gemcitabine (1 g\/m2 on day 1) and oxaliplatin (100 mg\/m2 on day 1) combined with tislelizumab (200 mg on day 2) at 21-day intervals, followed by tislelizumab maintenance (every 2 months for 2 years). The main outcome measure was the best complete remission rate. As of August 2022, a total of 30 patients had been consecutively enrolled and given induction therapy. The best overall response rate and complete remission rate were 100% (95% confidence interval [CI]: 88.4-100%) and 96.7% (95% CI: 82.8-99.9%), respectively. The median duration of follow-up after initiation of T-GemOx was 15.8 months. The 12-month progression-free survival rate without autologous stem cell transplant was 96% (95% CI: 74.8-99.4%). There were 122 adverse events recorded, of which 93.4% were grade 1 or 2. Thrombocytopenia (10%) and anemia (6.7%) were the most common grade 3 or 4 adverse events. Overall, T-GemOx demonstrated promising antitumor activity with manageable toxicities as a salvage treatment for relapsed or refractory cHL. A longer follow-up duration is required to determine whether maintenance therapy with tislelizumab rather than transplantation can be curative following such a highly active regimen. This trial was registered with the Chinese Clinical Trials Registry (http:\/\/www.chictr.org.cn) on June 1, 2020, identifier ChiCTR2000033441.<\/jats:p>","DOI":"10.3324\/haematol.2022.282266","type":"journal-article","created":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T03:59:27Z","timestamp":1674705567000},"page":"2146-2154","source":"Crossref","is-referenced-by-count":26,"title":["Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trial"],"prefix":"10.3324","volume":"108","author":[{"given":"Kaiyang","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongling","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huayuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,1,26]]},"reference":[{"key":"50541","doi-asserted-by":"crossref","unstructured":"Brice P, de Kerviler E, Friedberg JW. Classical Hodgkin lymphoma. Lancet. 2021; 398(10310):1518-1527.","DOI":"10.1016\/S0140-6736(20)32207-8"},{"key":"50542","doi-asserted-by":"crossref","unstructured":"Shanbhag S, Ambinder RF. Hodgkin lymphoma: a review and update on recent progress. CA Cancer J Clin. 2018; 68(2):116-132.","DOI":"10.3322\/caac.21438"},{"key":"50543","doi-asserted-by":"crossref","unstructured":"Engert A, Raemaekers J. Treatment of early-stage Hodgkin lymphoma. Semin Hematol. 2016; 53(3):165-170.","DOI":"10.1053\/j.seminhematol.2016.05.004"},{"key":"50544","doi-asserted-by":"crossref","unstructured":"Vassilakopoulos TP, Johnson PW. Treatment of advanced-stage Hodgkin lymphoma. Semin Hematol. 2016; 53(3):171-179.","DOI":"10.1053\/j.seminhematol.2016.05.006"},{"key":"50545","doi-asserted-by":"crossref","unstructured":"Roemer MG, Advani RH, Ligon AH. PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol. 2016; 34(23):2690-2697.","DOI":"10.1200\/JCO.2016.66.4482"},{"key":"50546","doi-asserted-by":"crossref","unstructured":"Green MR, Monti S, Rodig SJ. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010; 116(17):3268-3277.","DOI":"10.1182\/blood-2010-05-282780"},{"key":"50547","doi-asserted-by":"crossref","unstructured":"Carey CD, Gusenleitner D, Lipschitz M. Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. Blood. 2017; 130(22):2420-2430.","DOI":"10.1182\/blood-2017-03-770719"},{"key":"50548","doi-asserted-by":"crossref","unstructured":"Armand P, Engert A, Younes A. Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol. 2018; 36(14):1428-1439.","DOI":"10.1200\/JCO.2017.76.0793"},{"key":"50549","doi-asserted-by":"crossref","unstructured":"Chen R, Zinzani PL, Lee HJ. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood. 2019; 134(14):1144-1153.","DOI":"10.1182\/blood.2019000324"},{"key":"50550","doi-asserted-by":"crossref","unstructured":"Zhang T, Song X, Xu L. The binding of an anti-PD-1 antibody to Fc\u03b3R\u0399 has a profound impact on its biological functions. Cancer Immunol Immunother. 2018; 67(7):1079-1090.","DOI":"10.1007\/s00262-018-2160-x"},{"key":"50551","doi-asserted-by":"crossref","unstructured":"Dahan R, Sega E, Engelhardt J, Selby M, Korman AJ, Ravetch JV. Fc\u03b3Rs modulate the anti-tumor activity of antibodies targeting the PD-1\/PD-L1 axis. Cancer Cell. 2015; 28(4):543.","DOI":"10.1016\/j.ccell.2015.09.011"},{"key":"50552","doi-asserted-by":"crossref","unstructured":"Hong Y, Feng Y, Sun H. Tislelizumab uniquely binds to the CC' loop of PD-1 with slow-dissociated rate and complete PD-L1 blockage. FEBS Open Bio. 2021; 11(3):782-792.","DOI":"10.1002\/2211-5463.13102"},{"key":"50553","doi-asserted-by":"crossref","unstructured":"Lee SH, Lee HT, Lim H, Kim Y, Park UB, Heo Y-S. Crystal structure of PD-1 in complex with an antibody-drug tislelizumab used in tumor immune checkpoint therapy. Biochem Biophys Res Commun. 2020; 527(1):226-231.","DOI":"10.1016\/j.bbrc.2020.04.121"},{"key":"50554","doi-asserted-by":"crossref","unstructured":"Lee A, Keam SJ. Tislelizumab: first approval. Drugs. 2020; 80(6):617-624.","DOI":"10.1007\/s40265-020-01286-z"},{"key":"50555","doi-asserted-by":"crossref","unstructured":"Song Y, Gao Q, Zhang H. Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study. Leukemia. 2020; 34(2):533-542.","DOI":"10.1038\/s41375-019-0545-2"},{"key":"50556","doi-asserted-by":"crossref","unstructured":"Shi Y, Su H, Song Y. Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2019; 6(1):e12-e19.","DOI":"10.1016\/S2352-3026(18)30192-3"},{"key":"50557","doi-asserted-by":"crossref","unstructured":"Song Y, Wu J, Chen X. A single-arm, multicenter, phase II study of camrelizumab in relapsed or refractory classical Hodgkin lymphoma. Clin Cancer Res. 2019; 25(24):7363-7369.","DOI":"10.1158\/1078-0432.CCR-19-1680"},{"key":"50558","doi-asserted-by":"crossref","unstructured":"Gutierrez A, Rodriguez J, Martinez-Serra J. Gemcitabine and oxaliplatinum: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma. Onco Targets Ther. 2014; 7:2093-2100.","DOI":"10.2147\/OTT.S70264"},{"key":"50559","doi-asserted-by":"crossref","unstructured":"Romano A, Parrinello NL, Vetro C. Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin lymphoma patients treated up-front with a risk-adapted strategy. Br J Haematol. 2015; 168(5):689-700.","DOI":"10.1111\/bjh.13198"},{"key":"50560","doi-asserted-by":"crossref","unstructured":"Law AMK, Valdes-Mora F, Gallego-Ortega D. Myeloid-derived suppressor cells as a therapeutic target for cancer. Cells. 2020; 9(3):561.","DOI":"10.3390\/cells9030561"},{"key":"50561","doi-asserted-by":"crossref","unstructured":"Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+\/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res. 2005; 11(18):6713-6721.","DOI":"10.1158\/1078-0432.CCR-05-0883"},{"key":"50562","doi-asserted-by":"crossref","unstructured":"Gonzalez-Aparicio M, Alzuguren P, Mauleon I. Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice. Gut. 2011; 60(3):341-349.","DOI":"10.1136\/gut.2010.211722"},{"key":"50563","doi-asserted-by":"crossref","unstructured":"Nowak AK, Lake RA, Marzo AL. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol. 2003; 170(10):4905-4913.","DOI":"10.4049\/jimmunol.170.10.4905"},{"key":"50564","doi-asserted-by":"crossref","unstructured":"Liu WM, Fowler DW, Smith P, Dalgleish AG. Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br J Cancer. 2010; 102(1):115-123.","DOI":"10.1038\/sj.bjc.6605465"},{"key":"50565","doi-asserted-by":"crossref","unstructured":"Tesniere A, Schlemmer F, Boige V. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene. 2010; 29(4):482-491.","DOI":"10.1038\/onc.2009.356"},{"key":"50566","doi-asserted-by":"crossref","unstructured":"Mei MG, Lee HJ, Palmer JM. Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE. Blood. 2022; 139(25):3605-3616.","DOI":"10.1182\/blood.2022015423"},{"key":"50567","doi-asserted-by":"crossref","unstructured":"Advani RH, Moskowitz AJ, Bartlett NL. Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. Blood. 2021; 138(6):427-438.","DOI":"10.1182\/blood.2020009178"},{"key":"50568","doi-asserted-by":"crossref","unstructured":"Moskowitz AJ, Shah G, Sch\u00f6der H. Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma. J Clin Oncol. 2021; 39(28):3109-3117.","DOI":"10.1200\/JCO.21.01056"},{"key":"50569","doi-asserted-by":"crossref","unstructured":"Bryan LJ, Casulo C, Allen P. Pembrolizumab (PEM) added to ICE chemotherapy results in high complete metabolic response rates in relapsed\/refractory classic Hodgkin lymphoma (cHL): a multi-institutional phase II trial. Blood. 2021; 138(Suppl 1):229.","DOI":"10.1182\/blood-2021-145111"},{"key":"50570","doi-asserted-by":"crossref","unstructured":"Nie J, Wang C, Liu Y. Addition of low-dose decitabine to anti-PD-1 antibody camrelizumab in relapsed\/refractory classical Hodgkin lymphoma. J Clin Oncol. 2019; 37(17):1479-1489.","DOI":"10.1200\/JCO.18.02151"},{"key":"50571","doi-asserted-by":"crossref","unstructured":"Merryman RW, Redd RA, Nishihori T. Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. Blood Adv. 2021; 5(6):1648-1659.","DOI":"10.1182\/bloodadvances.2020003556"},{"key":"50572","doi-asserted-by":"crossref","unstructured":"Mochkin N, Sarzhevskiy V, Protopopova Y. Feasibility of ASCT after anti-PD-1 therapy for R\/R classical Hodgkin lymphoma. Hemasphere. 2022; 6(S3):981-982.","DOI":"10.1097\/01.HS9.0000847232.50505.64"},{"key":"50573","doi-asserted-by":"crossref","unstructured":"Manson G, Brice P, Herbaux C. Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2021; 48(4):1144-1153.","DOI":"10.1007\/s00259-020-05015-2"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.282266\/75310","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.282266\/75884","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10961\/75310","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:03:20Z","timestamp":1794045800000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2022.282266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,26]]},"references-count":33,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2022.282266","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1,26]]}}}